Neutrolis

About Neutrolis

Neutrolis is a biotechnology company focused on developing first-in-class precision therapies for autoimmune and inflammatory diseases. The company specializes in neutralizing Neutrophil Extracellular Traps (NETs), which are a fundamental and pathological source of extracellular DNA involved in these diseases. Neutrolis aims to revolutionize patient care by targeting the dark side of DNA, providing innovative treatments that address the scale and structure of extracellular DNA produced by NETosis.

Neutrolis operates in the biopharmaceutical market, serving patients suffering from autoimmune and inflammatory conditions. The company's business model revolves around research and development (R&D) of novel therapies, which are then brought to market through collaborations with pharmaceutical companies and healthcare providers. Revenue is generated through partnerships, licensing agreements, and potentially direct sales of their therapeutic products.

Neutrolis is actively seeking collaborators to help achieve its vision and maximize patient impact. The company leverages scientific advancements and a deep understanding of DNA's role in the immune response to create effective treatments.